Third Åland islands conference on von Willebrand disease, 26-28 September 2012: Meeting report

Haemophilia

Volumn 19, Issue SUPPL3, 2013, Pages 1-18

  Berntorp, E ^a   Fuchs, B ^b   Makris, M ^c   Montgomery, R ^d   Flood, V ^e   O'Donnell, J S ^f   Federici, A B ^g   Lillicrap, D ^h   James, P ^h   Budde, U ⁱ   Morfini, M ^j   Petrini, P ^k   Austin, S ^l   Kannicht, C ^b   Jimenez Yuste V ^m   Lee, C ⁿ  

^a LUND UNIVERSITY   (Sweden)

^b Octapharma RandD   (Germany)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d BLOOD RESEARCH INSTITUTE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f ST JAMES S HOSPITAL   (Ireland)

^g UNIVERSITY OF MILAN   (Italy)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ Medilys Laborgesellschaft mbH   (Germany)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l ST GEORGE S HOSPITAL   (United Kingdom)

^m UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Factor VIII; Genetics; Inhibitors; Pharmacokinetics; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; RISTOCETIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANGIODYSPLASIA; ANGIOGENESIS; CONSENSUS DEVELOPMENT; GENDER; GYNECOLOGIST; HUMAN; LIFESPAN; MEASUREMENT; MEDICAL SPECIALIST; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; THROMBOCYTE; VON WILLEBRAND DISEASE;

ANIMALS; FACTOR VIII; FEMALE; HUMANS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84873425397     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12078     Document Type: Review

References (96)

1. Von Willebrand EA. Hereditär pseudohemofili. Finska Läkarsällskapets Handl 1926; 67: 7-112.
2. Berntorp E, Ingerslev J, Schulman S. von Willebrand disease: an update in the Åland islands. Summary of a Nordic symposium on von Willebrand disease, 24-25 September 1998, Mariehamn, Åland. Haemophilia 1999; 5(Suppl. 2): 1-6.
3. Berntorp E, Peake I, Budde U et al. von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia 2012; 18(Suppl. 6): 1-13.
4. Ruggeri ZM, Ruggeri ZM. Platelet and von Willebrand factor interactions at the vessel wall. Hamostaseologie 2004; 24: 1-11.
5. Sadler JE, Grainick HR. Commentary: a new classification for von Willebrand disease. Blood 1994; 84: 676-9.
6. Cosemans JM, Schols SE, Stefanini L et al. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood 2011; 117: 651-60.
7. Matsushita T, Dong Z, Sadler JE. von Willebrand's factor and von Willebrand's disease. Curr Opin Hematol 1994; 1: 362-8.
8. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-6.
9. Fischer BE, Thomas KB, Schlokat U, Dorner F. Triplet structure of human von Willebrand factor. Biochem J 1998; 331(Pt 2): 483-8.
10. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-82.
11. Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmie B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 7503-7.
12. Fuchs B, de Witt S, Solecka BA et al. Distinct role of von Willebrand factor triplet bands in glycoprotein Ib-dependent platelet adhesion and thrombus formation under flow. Sem Thromb Hemost 2013; in press.
13. Starke RD, Ferraro F, Paschalaki KE et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011; 117: 1071-80.
14. Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res 2006; 118(Suppl. 1): S13-7.
15. Vincentelli A, Susen S, Le Tourneau T et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-9.
16. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease with angiodysplasia. Thromb Haemost 1993; 70: 546.
17. Abshire TC, Federici AB, Alvarez MT et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19: 76-81.
18. Flood VH, Gill JC, Morateck PA et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117: e67-74.
19. Flood VH, Gill JC, Morateck PA et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116: 280-6.
20. Flood VH, Friedman KD, Gill JC et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7: 1832-9.
21. Flood VH, Lederman CA, Wren JS et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost 2010; 8: 1431-3.
22. Flood VH, Gill JC, Christopherson PA et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost 2012; 10: 1417-24.
23. Flood VH, Gill JC, Christopherson PA et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost 2012; 10: 1425-32.
24. Sultan Y, Jeanneau C, Lamaziere J, Maisonneuve P, Caen JP. Platelet factor VIII-related antigen: studies in vivo after transfusion in patients with von Willebrand disease. Blood 1987; 51: 751-61.
25. Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost 2002; 87: 990-6.
26. McGrath RT, van den Biggelaar M, Byrne B et al. Platelet-derived von Willebrand factor glycosylation mediates resistance to ADAMTS13 proteolysis. J Thromb Haemost 2011; 9(Suppl. 2): 735-6 Abstract: O-TH-046.
27. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106: 1988-91.
28. McGrath RT, McKinnon TA, Byrne B et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood 2010; 115: 2666-73.
29. Williams SB, McKeown LP, Krutzsch H, Hansman K, Gralnick HR. Purification and characterization of human platelet von Willebrand factor. Br J Haematol 1994; 88: 582-91.
30. Nichols TC, Samama CM, Bellinger DA et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci 1995; 92: 2455-9.
31. Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost 2012; 10: 1646-52.
32. Mannucci PM, Lombardi R, Bader R et al. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66: 796-802.
33. Fressinaud E, Federici AB, Castaman G et al. The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease. Br J Haematol 1994; 86: 327-32.
34. Tosetto A, Rodegheiro F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2006; 4: 766-73.
35. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the Europen study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
36. Castaman G, Tosetto A, Cappelletti A et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res 2010; 126: 227-31.
37. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008; 111: 3998-4003.
38. Castaman G, Lethagen S, Federici AB et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM-1VWD. Blood 2008; 111: 3531-9.
39. Orstavik KH. Genetics of plasma concentration of von Willebrand factor. Folia Haematologica 1990; 117: 527-31.
40. James PD, Notley C, Hegadorn C et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109: 145-54.
41. Cumming A, Grundy P, Keeney S et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-41.
42. Bellissimo DB, Christopherson PA, Flood VH et al. Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2012; 119: 2135-40.
43. Campos M, Sun W, Yu F et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117: 5224-30.
44. Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999; 93: 4277-83.
45. Hough C, Cameron CL, Notley CR et al. Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoter. J Thromb Haemost 2008; 6: 1183-90.
46. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
47. Smith NL, Chen MH, Dehghan A et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-92.
48. Lemmerhirt HL, Shavit JA, Levy GG, Cole SM, Long JC, Ginsburg D. Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene. Blood 2006; 108: 3061-7.
49. Shavit JA, Manichaikul A, Lemmerhirt HL, Broman KW, Ginsburg D. Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice. Blood 2009; 114: 5368-74.
50. Mohlke KL, Purkayastha AA, Westrick RJ et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999; 96: 111-20.
51. Souto JC, Almasy L, Soria JM et al. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost 2003; 89: 468-74.
52. Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
53. Bowman M, Mundell G, Grabell J et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-6.
54. Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7: 1418-21.
55. Rodeghiero F, Tosetto A, Abshire T et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 2063-5.
56. International Society on Thrombosis and Haemostasis. Bleeding Assessment Tool. Available at http://bh.rockefeller.edu/ISTH-BATR/. Accessed October 2, 2012.
57. Ganderton T, Wong JWH, Schroeder C, Hogg PJ. Lateral self-association of VWF involves the Cys2431-2453 disulfide/dithiol in the C2 domain. Blood 2011; 118: 5312-8.
58. Yeh H-C, Zhou Z, Choi H et al. Disulfide reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost 2010; 8: 2778-88.
59. Gill JC. Treatment of urgent bleeding in von Willebrand disease. Thromb Res 2007; 120(Suppl. 1): S21-5.
60. Mannucci PM, Tenconi PM, Castaman G, Rodegheiro F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130-7.
61. Menarche D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia 1998; 4(Suppl. 3): 44-7.
62. Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS; Wilate PK Study Investigators. Study Investigators. The pharmacokinetic diversity of two von Willebrand factor (VWF/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. Thromb Haemost 2011; 106: 279-88.
63. Björkman S, Blanchette VS, Fischer K et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 730-6.
64. Björkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
65. Biss TT, Blanchette VS, Clark DS et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8: 950-6.
66. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005; 27: 330-2.
67. Morfini M. Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter. Haemophilia 2011; 17: 846-8.
68. Nilsson IM, Blombäck B, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35-57.
69. Di Paola J, Lethagen S, Gill J et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. Haemophilia 2011; 17: 752-8.
70. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
71. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
72. van Schooten CJ, Shahbazi S, Groot E et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008; 112: 1704-12.
73. Lenting PJ, Westein E, Terraube V et al. An experimental model to study the in vivo survival of von Willebrand factor. J Biol Chem 2004; 279: 12102-9.
74. Badirou I, Kurdi M, Rayes J et al. von Willebrand factor clearance does not involve proteolysis by ADAMTS-13. J Thromb Haemost 2010; 8: 2338-40.
75. Fijnvandraat K, Peters M, ten Crate JW. Inter-individual variation in half-life of infuse recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
76. Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia 1999; 5: 88-95.
77. Eikenboom JC, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002; 87: 252-7.
78. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene delations correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459-65.
79. Ngo KY, Glotz VT, Koziol JA et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
80. Schneppenheim R, Castaman G, Federici AB et al. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost 2007; 5: 722-8.
81. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol 1995; 386: 87-92.
82. Federici AB, Bucciarelli P, Castaman G et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37: 511-21.
83. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 9: 303-8.
84. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-55.
85. Type 3 von Willebrand international registries inhibitor prospective study (3WINTERS-IPS). Available at http://www.vwd-3winters-ips.com/. Accessed October 23, 2012.
86. Dilley A, Drews C, Miller C et al. von Willebrand disease and other inherited bleeding disrorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 630-6.
87. Kadir RA, Economides DL, Sabin CL, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485-9.
88. Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004; 10: 158-61.
89. von Mackensen S. Quality of life in women with bleeding disorders. Haemophilia 2011; 17(Suppl. 1): 33-7.
90. Demers C, Derzko C, David M. Society of Obstetricians and Gynaecologists of Canada. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95: 75-87.
91. James AH, Kouides PA, Abdul-Kadir R et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international panel. Am J Obstet Gynecol 2009; 201: 12-e1-8.
92. Philipp CS, Faiz A, Heit JA et al. Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol 2011; 204: 209.e1-7.
93. Shankar M, Sabin CA, Economides D, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. Br J Obstet Gynaecol 2004; 111: 734-40.
94. Lee CA, Kadir RA, Kouides PA, eds. Inherited Bleeding Disorders in Women. UK: Wiley-Blackwell, 2009.
95. Lee CA, Chi C, Shiltagh N et al. Review of a multidisciplinary clinic for women with inherited bleeding disorders. Haemophilia 2009; 15: 359-60.
96. NICE Guideline: Heavy menstrual bleeding. January 2007. Available at http://guidance.nice.org.uk/CG44/Guidance/pdf/English. Accessed October 7, 2012.